Skip to Content
Merck
CN

EHU095931

MISSION® esiRNA

targeting human NHEJ1

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

NACRES:
NA.51
UNSPSC Code:
41105324
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


description

Powered by Eupheria Biotech

Quality Level

product line

MISSION®

form

lyophilized powder

esiRNA cDNA target sequence

CCCAACATTTGATTCGTCCTCTGATGGGCATGAGTCTGGCATTACAGTGCCAAGTGAGGGAGCTAGCAACGTTACTTCATATGAAAGACCTAGAGATCCAAGACTACCAGGAGAGTGGGGCTACGCTGATTCGAGATCGATTGAAGACAGAACCATTTGAAGAAAATTCCTTCTTGGAACAATTTATGATAGAGAAACTGCCAGAGGCATGCAGCATTGGTGATGGAAAGCCCTTTGTCATGAATCTGCAGGATCTGTATATGGCAGTCACCACACAAGAGGTCCAAGTGGGACAGAAGCATCA

Ensembl | human accession no.

NCBI accession no.

shipped in

ambient

storage temp.

−20°C

Gene Information

human ... NHEJ1(79840)

General description

MISSION esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.

For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.

Legal Information

MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany


Storage Class

10 - Combustible liquids

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

新产品

This item has



Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library



Ryan Robb et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 25(15), 4749-4760 (2019-05-18)
Activating BRAF mutations, most commonly BRAFV600E, are a major oncogenic driver of many cancers. We explored whether BRAFV600E promotes radiation resistance and whether selectively targeting BRAFV600E with a BRAF inhibitor (vemurafenib, BRAFi) sensitizes BRAFV600E thyroid cancer cells to radiotherapy. Immunoblotting



Global Trade Item Number

SKUGTIN
EHU095931-20UG04061828599912
EHU095931-50UG04061828365401